DADC
CRBP icon

D.A. Davidson & Co’s Corbus Pharmaceuticals CRBP Stock Holding History

D.A. Davidson & Co’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-724
Closed -$27K – 1157
2020
Q4 		$27K Sell
724
-773
-52% -$28.9K ﹤0.01% 1012
2020
Q3 		$81K Sell
1,497
-413
-22% -$74.8K ﹤0.01% 929
2020
Q2 		$481K Buy
1,910
+107
+6% +$21.6K 0.01% 608
2020
Q1 		$283K Sell
1,803
-34
-2% -$5.75K 0.01% 766
2019
Q4 		$301K Buy
1,837
+17
+0.9% +$2.51K ﹤0.01% 818
2019
Q3 		$266K Buy
1,820
+136
+8% +$23.7K ﹤0.01% 819
2019
Q2 		$350K Hold
1,684
– – 0.01% 737
2019
Q1 		$351K Buy
1,684
+469
+39% +$103K 0.01% 802
2018
Q4 		$213K Buy
1,215
+526
+76% +$105K ﹤0.01% 955
2018
Q3 		$156K Buy
+689
New +$111K ﹤0.01% 1090

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.A. Davidson & Co's CRBP Position: Q1 2021 in Review

D.A. Davidson & Co sold out of Corbus Pharmaceuticals (CRBP) in Q1 2021, closing a stake of 724 shares — an estimated $27K sold.

D.A. Davidson & Co first reported a position in CRBP in Q3 2018 and held it in 10 quarters. The position peaked at $481K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2021.

  • D.A. Davidson & Co reported no remaining Corbus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • D.A. Davidson & Co sold 724 Corbus Pharmaceuticals shares in Q1 2021, an estimated $27K.
  • D.A. Davidson & Co first reported a position in Corbus Pharmaceuticals in Q3 2018 and held it in 10 quarters.
  • D.A. Davidson & Co's Corbus Pharmaceuticals position peaked at $481K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2021.

Based on D.A. Davidson & Co's 13F filing for Q1 2021, filed 7 May 2021.